Summary

U.S. Antibiotic Resistance Market Summary

The U.S. antibiotic esistance market size was estimated at USD 3.09 billion in 2024 and is projected to reach USD 3.99 billion by 2030, growing at a CAGR of 4.4% from 2025 to 2030. The market is expected to grow, driven by the rising misuse and overuse of antibiotics.

According to the CDC, more than 2.8 million antimicrobial-resistant infections are reported every year in the U.S., leading to 35,000 deaths. Moreover, the rise of public health concerns and the need for new antibiotic therapies are expected to drive market growth. According to the WHO, the overuse and misuse of antibiotics in animals, humans, and plants are the main reasons for the development of drug-resistant pathogens. Antibiotic resistance makes infections hard to treat and makes medical treatments, including cancer chemotherapy and surgeries such as cesarean sections and hip replacements, riskier. The market for antibiotic therapies is witnessing strong growth, driven by the urgent demand for treatments that can counteract rising resistance to existing drugs.

When a person contracts an infection caused by antibiotic-resistant bacteria, managing the illness becomes more challenging because fewer antibiotics can effectively treat the infection. In addition, these resistant bacteria can be transmitted to others, increasing the risk of wider spread. There are some rare instances where very few treatment options may be available.

U.S. Antibiotic Resistance Market Report Segmentation

This report forecasts revenue at the country level and analyzes the latest industry trends in each sub-segment from 2018 to 2030. For this study, Grand View Research has segmented the U.S. Antibiotic Resistance Market report based on disease, pathogen, drug class, mechanism of action, and distribution channel:

• Disease Outlook (Revenue in USD Million, 2018 - 2030)
• cUTI
• CDI
• ABSSSI
• HABP
• CABP
• cIAI
• BSI
• Pathogen Outlook (Revenue in USD Million, 2018 - 2030)
• E. coli
• klebsiella pneumoniae
• P. aeruginosa
• S. aureus
• baumannii
• Strep. Pneumoniae
• H. influenzae
• CDI
• Enterococcus fecium
• Drug Class Outlook (Revenue in USD Million; 2018 - 2030)
• Oxazolidinones
• Lipoglycopeptides
• Tetracyclines
• Combination therapies
• Cephalosporins
• Others
• Mechanism of Action Outlook (Revenue in USD Million; 2018 - 2030)
• Protein Synthesis Inhibitors
• Cell Wall Synthesis Inhibitors
• RNA Synthesis Inhibitors
• DNA Synthesis Inhibitors
• Others
• Distribution Channel Outlook (Revenue in USD Million; 2018 - 2030)
• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies

ページTOPに戻る

Table of Contents

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Disease
1.2.2. Pathogen
1.2.3. Drug Class
1.2.4. Mechanism of Action
1.2.5. Distribution Channel
1.2.6. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Disease outlook
2.2.2. Pathogen outlook
2.2.3. Drug Class outlook
2.2.4. Mechanism of Action
2.2.5. Distribution Channel
2.3. Competitive Insights
Chapter 3. U.S. Antibiotic Resistance Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.2. Market restraint analysis
Chapter 4. U.S. Antibiotic Resistance Market Analysis Tools
4.1. Industry Analysis - Porter’s
4.1.1. Supplier power
4.1.2. Buyer power
4.1.3. Substitution threat
4.1.4. Threat of new entrant
4.1.5. Competitive rivalry
4.2. PESTEL Analysis
4.2.1. Political landscape
4.2.2. Technological landscape
4.2.3. Economic landscape
4.3. U.S. Antibiotic Resistance Market: Pipeline Analysis
Chapter 5. U.S. Antibiotic Resistance Market: Disease Estimates & Trend Analysis
5.1. Disease Segment Dashboard
5.2. U.S. Antibiotic Resistance Market: Disease Movement Analysis
5.3. U.S. Antibiotic Resistance Market Size & Trend Analysis, by Disease, 2018 to 2030 (USD Million)
5.4. cUTI
5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.5. CDI
5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.6. ABSSSI
5.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.7. HABP
5.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.8. CABP
5.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.9. cIAI
5.9.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.10. BSI
5.10.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 6. U.S. Antibiotic Resistance Market: Pathogen Estimates & Trend Analysis
6.1. Pathogen Segment Dashboard
6.2. U.S. Antibiotic Resistance Market: Pathogen Movement Analysis
6.3. U.S. Antibiotic Resistance Market Size & Trend Analysis, by Pathogen, 2018 to 2030 (USD Million)
6.4. E. coli
6.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.5. klebsiella pneumoniae
6.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.6. P. aeruginosa
6.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.7. S. aureus
6.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.8. A. baumannii
6.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.9. Strep. Pneumoniae
6.9.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.10. H. influenzae
6.10.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.11. CDI
6.11.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.12. Enterococcus fecium
6.12.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 7. U.S. Antibiotic Resistance Market: Drug Class Estimates & Trend Analysis
7.1. Drug Class Segment Dashboard
7.2. U.S. Antibiotic Resistance Market: Drug Class Movement Analysis
7.3. U.S. Antibiotic Resistance Market Size & Trend Analysis, by Drug Class, 2018 to 2030 (USD Million)
7.4. Oxazolidinones
7.4.1. Market estimates and forecasts 2018 to 2030 (USD million)
7.5. Lipoglycopeptides
7.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
7.6. Tetracyclines
7.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
7.7. Combination therapies
7.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
7.8. Cephalosporins
7.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
7.9. Others
7.9.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 8. U.S. Antibiotic Resistance Market: Mechanism of Action Estimates & Trend Analysis
8.1. Mechanism of Action Segment Dashboard
8.2. U.S. Antibiotic Resistance Market: Mechanism of Action Movement Analysis
8.3. U.S. Antibiotic Resistance Market Size & Trend Analysis, by Mechanism of Action, 2018 to 2030 (USD Million)
8.4. Protein Synthesis Inhibitors
8.4.1. Market estimates and forecasts 2018 to 2030 (USD million)
8.5. Cell Wall Synthesis Inhibitors
8.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
8.6. RNA Synthesis Inhibitors
8.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
8.7. DNA Synthesis Inhibitors
8.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
8.8. Others
8.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 9. U.S. Antibiotic Resistance Market: Distribution Channel Estimates & Trend Analysis
9.1. Distribution Channel Segment Dashboard
9.2. U.S. Antibiotic Resistance Market: Distribution Movement Analysis
9.3. U.S. Antibiotic Resistance Market Size & Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
9.4. Retail Pharmacies
9.4.1. Market estimates and forecasts 2018 to 2030 (USD million)
9.5. Hospital Pharmacies
9.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
9.6. Online Pharmacies
9.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 10. Competitive Landscape
10.1. Recent Developments & Impact Analysis, By Key Market Participants
10.2. Company/Competition Categorization
10.3. Vendor Landscape
10.3.1. Key company heat map analysis, 2024
10.4. Company Profiles
10.4.1. Melinta Therapeutics
10.4.1.1. Company overview
10.4.1.2. Financial performance
10.4.1.3. Product benchmarking
10.4.1.4. Strategic initiatives
10.4.2. Merck & Co., Inc.
10.4.2.1. Company overview
10.4.2.2. Financial performance
10.4.2.3. Product benchmarking
10.4.2.4. Strategic initiatives
10.4.3. Melinta Therapeutics LLC
10.4.3.1. Company overview
10.4.3.2. Financial performance
10.4.3.3. Product benchmarking
10.4.3.4. Strategic initiatives
10.4.4. Theravance Biopharma.
10.4.4.1. Company overview
10.4.4.2. Financial performance
10.4.4.3. Product benchmarking
10.4.4.4. Strategic initiatives
10.4.5. Paratek Pharmaceuticals, Inc.
10.4.5.1. Company overview
10.4.5.2. Financial performance
10.4.5.3. Product benchmarking
10.4.5.4. Strategic initiatives
10.4.6. Seres Therapeutics
10.4.6.1. Company overview
10.4.6.2. Financial performance
10.4.6.3. Product benchmarking
10.4.6.4. Strategic initiatives
10.4.7. AbbVie Inc.
10.4.7.1. Company overview
10.4.7.2. Financial performance
10.4.7.3. Product benchmarking
10.4.7.4. Strategic initiatives